

National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* ("the Act"), National Shipbuilding Research Program ("NSRP") has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Vigor Marine LLC, Seattle, WA, has been added as a party to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and NSRP intends to file additional written notifications disclosing all changes in membership.

On March 13, 1998, NSRP filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to Section 6(b) of the Act on January 29, 1999 (64 FR 4708).

The last notification was filed with the Department on January 16, 2019. A notice was published in the **Federal Register** pursuant to Section 6(b) of the Act on February 12, 2019 (84 FR 3492).

Suzanne Morris,

Chief, Premerger and Division Statistics Unit, Antitrust Division.

[FR Doc. 2019-08995 Filed 5-1-19; 8:45 am]

BILLING CODE 4410-11-P

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993—Medical Technology Enterprise Consortium

Notice is hereby given that, on April 8, 2019, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* ("the Act"), Medical Technology Enterprise Consortium ("MTEC") has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Securisyn Medical, LLC, Highlands Ranch, CO; Polaris Alpha Advanced Systems, Inc., Aberdeen Proving Ground, MD; Arrevus, Inc.,

Raleigh, NC; Initiate Government Solutions, LLC, North Palm Beach, FL; 7-SIGMA Incorporated, Minneapolis, MN; MAE Group, Deerfield, NH; Radical Concepts LLC, Brooklyn, NY; Next Generation Stretcher Ltd, Raman gan, Israel; Pop Test Oncology LLC aka Palisades Therapeutics, Cliffside Park, NJ; George Mason University, Manassas, VA; Phagelux (Canada) Inc., Montréal, CANADA; MY01 Inc., Montreal, CANADA; MilanaPharm, LLC, Tallassee, AL; Leidos, Inc., Reston, VA; InfraScan, Inc., Philadelphia, PA; NuShores Biosciences LLC, Little Rock, AR; Seran Bioscience, Bend, OR; Celularity, Warren, NJ; Droper Med America, LLC, Elgin, SC; tesa Labtec GmbH, Langenfeld, GERMANY; Bio Med Sciences, Inc., Allentown, PA; Uluru Inc., Addison, TX; Trailhead Biosystems Inc., Cleveland, OH; 410 Medical, Inc., Durham, NC; Knowledge Driven LLC, Alexandria, VA; Arsenal Medical, Inc., Watertown, MA; University of North Carolina, Institute for Trauma Recovery, Chapel Hill, NC; Prep Tech, LLC, Westlake, LA; 21 MedTech, LLC, Burlington, NC; Integrum Scientific, LLC, Greensboro, NC; HYPR Life Sciences, Inc., Pilot Mountain, NC; X-Therma Inc., Richmond, CA; VoluMetrix LLC, Nashville, TN; Howmedica Osteonics Corp. dba Stryker Orthopaedics, Mahwah, NJ; NeuEsse Inc., Dunbar, PA; The Geneva Foundation, Tacoma, WA; Scinus Cell Expansion B.V., Bilthoven, THE NETHERLANDS; Akron Biotechnology, LLC, Boca Raton, FL; RoosterBio Inc., Frederick, MD; Aptitude Medical Systems, Santa Barbara, CA; Rho Federal Systems Division, Inc. (RhoFED), Chapel Hill, NC; HeadsafelP Pty Ltd Bronte, AUSTRALIA; Truecath Inc., Camarillo, CA; Solutions Through Innovative Technologies, Inc., Fairborn, OH; Sempulse, LLC, San Marcos, TX; The Curators of the University of Missouri on behalf of the University of Missouri-Kansas City, Kansas City, MO; Cognitive Medical Systems, Inc., San Diego, CA; Hemoclear B.V., Zwolle, NETHERLANDS; Immunexpress Inc., Seattle, WA; Klox Technologies, Inc., Laval, CANADA; Opticyte, Inc., Seattle, WA; Physcient, Inc., Durham, NC; ActiBioMotion, LLC, Coralville, IA; Detact Diagnostics BV, Gronigen, THE NETHERLANDS; SurgiBox Inc., Brookline, MA; Cincinnati Automation & Mechatronics, LLC, Beavercreek, OH; and Molecular Biologicals, Pasadena, TX; have been added as parties to this venture.

Also, Tallinn University of Technology, Tallin, Estonia; National

Trauma Institute dba Coalition for National Trauma Research, Marietta, TX; East Carolina University, Greenville, NC; EyeSonix LLC, Long Beach, CA; ElMindA Ltd., Herzliya, ISRAEL; Propagenix Inc., Rockville, MD; Studio Kinection, Inc. dba Kinection, Napa, CA; The Ohio State University, Columbus, OH; Elemance, LLC, Clemmons, NC; J. Craig Venter Institute (JCVI), Rockville, MD; LambdaVision Incorporated, Farmington, CT; Michigan State University, East Lansing, MI; Corvid Technologies, Mooresville, NC; Spire, San Francisco, CA; United Solutions, LLC, Rockville, MD; Aleo BME, Inc., State College, PA; Cell Guidance Systems Ltd, Cambridge, UK; Cole Engineering Services, Inc., Orlando, FL; FlexDex, Inc., Brighton, MI; Fortuna Fix, London, UK; Hypatia Project, Reston, VA; and MiMedx Group Inc., Marietta, GA; have withdrawn as parties to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and MTEC intends to file additional written notifications disclosing all changes in membership.

On May 9, 2014 MTEC filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to Section 6(b) of the Act on June 9, 2014 (79 FR 32999).

The last notification was filed with the Department on January 28, 2019. A notice was published in the **Federal Register** pursuant to Section 6(b) of the Act on February 28, 2019 (84 FR 6824).

Suzanne Morris,

Chief, Premerger and Division Statistics Unit, Antitrust Division.

[FR Doc. 2019-08997 Filed 5-1-19; 8:45 am]

BILLING CODE 4410-11-P

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993—Pistoia Alliance, Inc.

Notice is hereby given that, on April 8, 2019, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* ("the Act"), Pistoia Alliance, Inc. has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were

filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Konrad Krawczyk (individual member), Hamburg, GERMANY; Waters Technologies Company, Milford, MA; Genomics England, London, UNITED KINGDOM; Brian Frenzel (individual member), Mountain View, CA; Kirk Brote (individual member), Durham, NH; Numerate Inc., San Francisco, CA; Valery Tkachenko (individual member), Rockville, MD; The Broad Institute Inc., Cambridge, MA; WuXi AppTec, Cambridge, MA; BioSistemika d.o.o., Ljubljana, SLOVENIA; Optibrium Limited, Cambridge, UNITED KINGDOM; Elixir, Cambridge, UNITED KINGDOM; L7 Informatics Inc., Dallas, TX; Alzheimer's Research UK, Cambridge, UNITED KINGDOM; and Yvonne Linney (individual member), Saratoga, CA, have been added as parties to this venture.

Also, Novaseek Research, Cambridge, MA; PRYV SA, Lausanne, SWITZERLAND; and Cyclica, Toronto, CANADA, have withdrawn as parties to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and Pistoia Alliance, Inc. intends to file additional written notifications disclosing all changes in membership.

On May 28, 2009, Pistoia Alliance, Inc. filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to Section 6(b) of the Act on July 15, 2009 (74 FR 34364).

The last notification was filed with the Department on January 28, 2019. A notice was published in the **Federal Register** pursuant to Section 6(b) of the Act on February 7, 2019 (84 FR 2569).

Suzanne Morris,

Chief, Premerger and Division Statistics Unit, Antitrust Division.

[FR Doc. 2019-08994 Filed 5-1-19; 8:45 am]

BILLING CODE 4410-11-P

DEPARTMENT OF JUSTICE

Notice of Lodging of Proposed Consent Decree Under the Clean Water Act

On April 26, 2019, the Department of Justice lodged a proposed Consent Decree with the United States District Court for the District of Montana in the lawsuit entitled *United States v.*

ExxonMobil Pipeline Company, Civil Action No. 1:19-cv-00048-SPW-TJC.

The United States filed this lawsuit against ExxonMobil Pipeline Company ("ExxonMobil") seeking civil penalties pursuant to Section 311(b)(7)(A) and (D) of the Clean Water Act ("CWA"), 33 U.S.C. 1321(b)(7)(A) and (D), and injunctive relief pursuant to Section 309(b) of the CWA, 33 U.S.C. 1319(b), as a result of the July 1, 2011 discharge of over 1,500 barrels of crude oil from the company's Silvertip Pipeline into the Yellowstone River near Laurel, Montana. The proposed Consent Decree requires ExxonMobil Pipeline Company to pay a civil penalty of \$1,050,000 to resolve the claims. The settlement proceeds will be deposited in the Oil Spill Liability Trust Fund. The proposed Consent Decree also requires ExxonMobil to take action at certain Silvertip Pipeline water crossings.

The publication of this notice opens a period for public comment on the consent decree. Comments should be addressed to the Assistant Attorney General, Environment and Natural Resources Division, and should refer to *United States v. ExxonMobil Pipeline Company*, D.J. Ref. No. 90-5-1-1-10332/1. All comments must be submitted no later than thirty (30) days after the publication date of this notice. Comments may be submitted either by email or by mail:

| <i>To submit comments:</i> | <i>Send them to:</i> |
|----------------------------|---|
| By email | <i>pubcomment-ees.enrd@usdoj.gov.</i> |
| By mail | Assistant Attorney General, U.S. DOJ—ENRD, P.O. Box 7611, Washington, DC 20044-7611. |

During the public comment period, the consent decree may be examined and downloaded at this Justice Department website: <https://www.justice.gov/enrd/consent-decrees>. We will provide a paper copy of the consent decree upon written request and payment of reproduction costs. Please mail your request and payment to: Consent Decree Library, U.S. DOJ—ENRD, P.O. Box 7611, Washington, DC 20044-7611.

Please enclose a check or money order for \$9.50 for the consent decree and appendices (25 cents per page reproduction cost) or \$7.50 for the

consent decree without appendix, payable to the United States Treasury.

Jeffrey Sands,

Assistant Section Chief, Environmental Enforcement Section, Environment and Natural Resources Division.

[FR Doc. 2019-08940 Filed 5-1-19; 8:45 am]

BILLING CODE 4410-15-P

DEPARTMENT OF JUSTICE

[OMB Number 1121-0100]

Agency Information Collection Activities; Proposed eCollection eComments Requested; Reinstatement, With Change, of a Previously Approved Collection for Which Approval Has Expired: 2019 Census of Jails

AGENCY: Bureau of Justice Statistics, Department of Justice.

ACTION: 30-Day notice.

SUMMARY: The Department of Justice (DOJ), Office of Justice Programs, Bureau of Justice Statistics, will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed information collection was previously published in the **Federal Register** Volume 84, Number 32, pages 4539-4541, on February 15, 2019, allowing a 60-day comment period. Following publication of the 60-day notice, the Bureau of Justice Statistics received seven comments. Responses to these comments will be included in the final clearance package submitted to OMB.

DATES: Comments are encouraged and will be accepted for 30 days until June 3, 2019.

FOR FURTHER INFORMATION CONTACT: If you have comments especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact Todd D. Minton, Bureau of Justice Statistics, 810 Seventh Street NW, Washington, DC 20531 (email: Todd.Minton@usdoj.gov; telephone: 202-305-9630).

SUPPLEMENTARY INFORMATION: Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points:

—Evaluate whether the proposed collection of information is necessary